ACAD - ACADIA Pharmaceuticals Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $34.33 DETAILS

Stock News

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived for approximately 90 days. The conference ca.

Jul 15, 2026 12:05 PM • businesswire.com

An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?

Principal Accounting Officer James Kihara sold 11,421 shares for a transaction value of approximately ~$298,000 on June 26, 2026. The sale represented 46.60% of Kihara's direct holdings and reduced direct ownership to 13,088 shares.

Jul 11, 2026 12:50 PM • fool.com

RPRX or ACAD: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?

Jul 09, 2026 08:40 AM • zacks.com

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company's global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia's executive leadership team. “Carl is a proven global leader with a stro.

Jul 06, 2026 05:04 AM • businesswire.com

ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome

Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.

Jun 29, 2026 08:16 AM • zacks.com

Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus

Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation. I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success.

Jun 29, 2026 07:19 AM • seekingalpha.com

Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?

Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Jun 29, 2026 06:40 AM • zacks.com

Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares are trading higher on Friday as the company is celebrating a positive recommendation from the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) regarding its drug DAYBU (trofinetide) for treating neurobehavioral symptoms of Rett syndrome in the European Union.

Jun 26, 2026 09:47 AM • benzinga.com

Why Acadia Pharmaceuticals Stock Is Soaring Today

Acadia Pharmaceuticals focuses on underserved rare diseases. Although they're (by definition) small markets, there's often little to no competition to treat rare and underserved diseases.

Jun 26, 2026 08:17 AM • fool.com

The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout

Acadia stock popped Friday after European regulators unexpectedly said they would recommend approval of the Rett syndrome drug, Daybu.

Jun 26, 2026 06:24 AM • investors.com

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by.

Jun 26, 2026 02:49 AM • businesswire.com

Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Jun 05, 2026 08:36 AM • zacks.com

ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE Growth

ACADIA Pharmaceuticals NASDAQ: ACAD executives used an RBC Capital Markets investor session to outline the company's clinical rationale for remlifanserin in Alzheimer's disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business development priorities.

May 19, 2026 06:15 AM • marketbeat.com

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12, 2026 06:10 PM • seekingalpha.com

ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms

ACADIA Pharmaceuticals NASDAQ: ACAD executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference.

May 12, 2026 04:25 PM • marketbeat.com

ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth

Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.

May 07, 2026 08:46 AM • zacks.com

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript

May 07, 2026 12:41 AM • seekingalpha.com

Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.11 per share a year ago.

May 06, 2026 02:25 PM • zacks.com

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We are very encouraged by the early enthusiasm for DAYBUE STIX, which is now broadly available in the U.S., and by the initial up.

May 06, 2026 12:05 PM • businesswire.com

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and.

Apr 30, 2026 12:05 PM • businesswire.com